{"id":"palcebo-carboplatin-etoposide-radiotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Radiation dermatitis"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1351","moleculeType":"Small molecule","molecularWeight":"371.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carboplatin is a platinum-based alkylating agent that cross-links DNA and prevents replication. Etoposide is a topoisomerase II inhibitor that causes DNA breaks during cell division. Radiotherapy delivers ionizing radiation to directly damage tumor DNA. Together, these modalities create multiple mechanisms of cancer cell death in a phase 3 trial context.","oneSentence":"This is a combination regimen using carboplatin and etoposide chemotherapy plus radiotherapy to kill cancer cells through DNA damage and cell cycle disruption, with placebo as a control arm.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:25:22.420Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Likely small cell lung cancer or other solid tumors (specific indication not provided)"}]},"trialDetails":[{"nctId":"NCT04691063","phase":"PHASE3","title":"The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC.","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-01-22","conditions":"Small-cell Lung Cancer","enrollment":486}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Palcebo; Carboplatin; Etoposide；Radiotherapy","genericName":"Palcebo; Carboplatin; Etoposide；Radiotherapy","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination regimen using carboplatin and etoposide chemotherapy plus radiotherapy to kill cancer cells through DNA damage and cell cycle disruption, with placebo as a control arm. Used for Likely small cell lung cancer or other solid tumors (specific indication not provided).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}